Regentis Biomaterials Ltd. RGNT

Annual Quarterly

No annual revenue total was found in Regentis Biomaterials Ltd.'s SEC filings.

Regentis Biomaterials Ltd. (RGNT) files with the SEC under industry code 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies. As of Dec 31, 2025 it held $7.4 million in cash and investments and $1.2 million in total debt.

Revenue
—
Net income
$-13.65M
Operating cash flow
$-1.38M
Free cash flow
—
EPS
$-24.16
Dividend per share
None
Shares outstanding
5.18M
Net cash
$6.18M
FY 2025
Operating margin
—

Company profile

Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Listed as
RGNT (NYSE)
Fiscal year ends
December 31
Incorporated in
Israel
Headquarters
Or Akiva
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1912966

Other Orthopedic, Prosthetic & Surgical Appliances & Supplies companies

All 29 Orthopedic, Prosthetic & Surgical Appliances & Supplies companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Operating income
-$7.0M
Net income
-$13.6M
Diluted EPS
-$24.16
Operating cash flow
-$1.4M
Total assets
$7.6M
Total liabilities
$2.9M
Stockholders' equity
$4.7M
Cash and investments
$7.4M
Total debt
$1.2M

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Oct 13, 2026 Oct 13, 2026
6-K Current report (foreign issuer) Sep 11, 2026 Jun 30, 2026
6-K Current report (foreign issuer) Jul 20, 2026 Jul 20, 2026
6-K Current report (foreign issuer) Jul 15, 2026 Jul 15, 2026
6-K Current report (foreign issuer) Jul 9, 2026 Jul 9, 2026
6-K Current report (foreign issuer) Jul 2, 2026 Jul 2, 2026

All 93 Regentis Biomaterials Ltd. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.